Support from seasoned global industry leaders

MimiX Biotheraperutics has appointed Andrew Williamson to its Board of Directors. Andrew is the President of Heraeus Medical, a company specializing in the development and commercialization of medical products and an investor in mimiX. With his experience, he will support the startup in accelerating the development of precision medicine. Established in 2019, the company leverages Sound Induced Morphogenesis (SIM), a proprietary technology that uses sound in conjunction with cells, stem cells, spheroids, organoids & bioactives, to create tissue-relevant architectures (bio-patterns). SIM replicates nature’s design strategy by controlling shape & function, the two fundamentals in developmental biology. Sound Induced Morphogenesis was developed as a result of 10+ years of research and development efforts incubated at the AO Foundation in Davos, Switzerland.

The company has embedded its base SIM technology into cymatiX®, a discovery platform for a large range of applications, from life sciences to drug development, cellular agriculture, and performance materials. The recent partnership with PreComb will see the companies combine their technologies to accelerate the process of personalized cancer drug profiling. PreComb is pioneering personalized cancer profiling with its proprietary 3DTwin® technology.

Artidis to benefit from Ajit Singh’s expertise
ARTIDIS AG, a clinical-stage medical technology company on a mission to shift the paradigm of cancer care from central lab to patient bedside, announced the appointment of Ajit Singh, to the ARTIDIS Board of Directors. As a member of the ARTIDIS Board of Directors, Singh will provide pivotal support to ARTIDIS as the company is approaching the commercialization phase. Singh will take an active role in bolstering the company’s strategy contributing his profound domain knowledge in oncology, medical imaging and digital health.

He is the former CEO of BioImagene, Siemens Oncology and Siemens Imaging Systems, as well as a faculty member at Stanford School of Medicine. In addition to deep scientific knowledge, he has a proven track record of leadership success in businesses with revenues ranging from USD 10 million to USD 2 billion, complemented with substantial M&A experience. Furthermore, he is an active partner and managing director of a Silicon Valley Venture Fund focused on early-stage technology, healthcare, and life science investments.

Lattice flow appoints Chairman of its Board
Zurich-based startup LatticeFlow AG, the leading artificial intelligence (AI) platform that can continuously improve model performance by automatically finding and fixing AI data and model errors, has welcomed Andre Boisvert as Chairman of its Board of Directors. Boisvert is a globally-recognized software executive with over 35-years of experience in sales, marketing, and R&D at companies such as IBM, Oracle Corporation, where he served as Senior Vice President of WW Marketing, and SAS Institute Inc, where he served as President & Chief Operating Officer.

After serving on boards of publicly traded technology companies, such as VA Linux and Sagent Technologies Inc. (NASDAQ:SGNT), Boisvert co-founded Pentaho, an open-source BI & Analytics company which was ultimately acquired by Hitachi Data Systems for over $500M. Since then, Boisvert has served on the board of multiple technology startups, many, which have been acquired by tech powerhouses like Microsoft, Oracle and SAP. Today, in addition to LatticeFlow AG, Boisvert serves on the board of directors of Tel Aviv-based Pyramid Analytics Inc, Montreal-based Dcbel Energy Inc, Minneapolis-based Clario Inc, and Dallas-based River Logic Inc. 

(Press release/RAN)